Latest news with #EU-GMP
Cision Canada
15-05-2025
- Business
- Cision Canada
Curaleaf International Launches a Range of Medical Cannabis Products in Australia
LONDON, May 15, 2025 /CNW/ -- Curaleaf International, part of Curaleaf Holdings, Inc. (TSX: CURA) a leading international provider of medical cannabis products, today announced the launch of Curaleaf branded products in Australia. This announcement marks the expansion of Curaleaf's presence in one of the world's fastest growing medical cannabis markets and underscores its commitment to local collaboration, clinical integrity, and patient care. The initial product offering, comprising four cannabis flower strains, will be distributed via Canngea, a licensed Australian manufacturer and wholesaler with a wealth of experience in medical cannabis. This partnership supports Curaleaf's vision to be the world's leading cannabis company by consistently delivering superior products and services. Over the coming months, patients and healthcare professionals in Australia can look forward to a broader portfolio and further innovative solutions offered by Curaleaf, including precision-dosed inhalation formats and popular strains already widely prescribed across the UK, Germany, and other key European markets. Juan Martinez, Head of Curaleaf International, commented: "Entering the Australian market is a significant milestone in our global strategy to expand access to high-quality, evidence-backed cannabis medicines. We're committed to supporting Australian patients and healthcare professionals with reliable, consistent products and the backing of one of the industry's most advanced supply chains." Boris Jordan, Chairman and CEO of Curaleaf, added: "Australia is an exciting and rapidly evolving market, expected to surpass $1 billion in annual sales next year, and this launch is a positive step forward in our strategy to extend our position as the global leader in cannabis. We're bringing a proven portfolio and a strong track record of innovation, with more to come." About Curaleaf International Curaleaf International is shaping the future of cannabis through its commitment to research and product excellence. Powered by a strong presence at all stages of the supply chain, its unique distribution network throughout Europe, Canada and Australasia brings together pioneering research with cutting-edge cultivation, extraction, and production. Amidst a rapid growth trajectory, the emphasis on quality and expertise aims to ensure the delivery of safe and legal cannabis. Curaleaf International's network includes a clinic, pharmacy, and laboratory in the UK; cultivation and EU-GMP processing facilities in Portugal; an EU-GMP processing, quality assurance and research site in Spain; Four20 Pharma wholesaler and distributor in Germany; a Polish wholesaler and clinic; and the EU-GMP producer Northern Green Canada. Curaleaf International is part of Curaleaf Holdings, Inc., a leading international producer and distributor of consumer cannabis products.
Associated Press
15-05-2025
- Business
- Associated Press
Curaleaf International Launches a Range of Medical Cannabis Products in Australia
LONDON, May 15, 2025 /PRNewswire/ -- Curaleaf International, part of Curaleaf Holdings, Inc. (TSX:CURA) a leading international provider of medical cannabis products, today announced the launch of Curaleaf branded products in Australia. This announcement marks the expansion of Curaleaf's presence in one of the world's fastest growing medical cannabis markets and underscores its commitment to local collaboration, clinical integrity, and patient care. The initial product offering, comprising four cannabis flower strains, will be distributed via Canngea, a licensed Australian manufacturer and wholesaler with a wealth of experience in medical cannabis. This partnership supports Curaleaf's vision to be the world's leading cannabis company by consistently delivering superior products and services. Over the coming months, patients and healthcare professionals in Australia can look forward to a broader portfolio and further innovative solutions offered by Curaleaf, including precision-dosed inhalation formats and popular strains already widely prescribed across the UK, Germany, and other key European markets. Juan Martinez, Head of Curaleaf International, commented: 'Entering the Australian market is a significant milestone in our global strategy to expand access to high-quality, evidence-backed cannabis medicines. We're committed to supporting Australian patients and healthcare professionals with reliable, consistent products and the backing of one of the industry's most advanced supply chains.' Boris Jordan, Chairman and CEO of Curaleaf, added: 'Australia is an exciting and rapidly evolving market, expected to surpass $1 billion in annual sales next year, and this launch is a positive step forward in our strategy to extend our position as the global leader in cannabis. We're bringing a proven portfolio and a strong track record of innovation, with more to come.' About Curaleaf International Curaleaf International is shaping the future of cannabis through its commitment to research and product excellence. Powered by a strong presence at all stages of the supply chain, its unique distribution network throughout Europe, Canada and Australasia brings together pioneering research with cutting-edge cultivation, extraction, and production. Amidst a rapid growth trajectory, the emphasis on quality and expertise aims to ensure the delivery of safe and legal cannabis. Curaleaf International's network includes a clinic, pharmacy, and laboratory in the UK; cultivation and EU-GMP processing facilities in Portugal; an EU-GMP processing, quality assurance and research site in Spain; Four20 Pharma wholesaler and distributor in Germany; a Polish wholesaler and clinic; and the EU-GMP producer Northern Green Canada. Curaleaf International is part of Curaleaf Holdings, Inc., a leading international producer and distributor of consumer cannabis products. Media Contact: Curaleaf International: Beth Sweet-Escott Head of Communications, Curaleaf International [email protected] View original content to download multimedia: SOURCE Curaleaf International
Yahoo
15-05-2025
- Business
- Yahoo
Curaleaf International Launches a Range of Medical Cannabis Products in Australia
LONDON, May 15, 2025 /PRNewswire/ -- Curaleaf International, part of Curaleaf Holdings, Inc. (TSX:CURA) a leading international provider of medical cannabis products, today announced the launch of Curaleaf branded products in Australia. This announcement marks the expansion of Curaleaf's presence in one of the world's fastest growing medical cannabis markets and underscores its commitment to local collaboration, clinical integrity, and patient care. The initial product offering, comprising four cannabis flower strains, will be distributed via Canngea, a licensed Australian manufacturer and wholesaler with a wealth of experience in medical cannabis. This partnership supports Curaleaf's vision to be the world's leading cannabis company by consistently delivering superior products and services. Over the coming months, patients and healthcare professionals in Australia can look forward to a broader portfolio and further innovative solutions offered by Curaleaf, including precision-dosed inhalation formats and popular strains already widely prescribed across the UK, Germany, and other key European markets. Juan Martinez, Head of Curaleaf International, commented: "Entering the Australian market is a significant milestone in our global strategy to expand access to high-quality, evidence-backed cannabis medicines. We're committed to supporting Australian patients and healthcare professionals with reliable, consistent products and the backing of one of the industry's most advanced supply chains." Boris Jordan, Chairman and CEO of Curaleaf, added: "Australia is an exciting and rapidly evolving market, expected to surpass $1 billion in annual sales next year, and this launch is a positive step forward in our strategy to extend our position as the global leader in cannabis. We're bringing a proven portfolio and a strong track record of innovation, with more to come." About Curaleaf InternationalCuraleaf International is shaping the future of cannabis through its commitment to research and product excellence. Powered by a strong presence at all stages of the supply chain, its unique distribution network throughout Europe, Canada and Australasia brings together pioneering research with cutting-edge cultivation, extraction, and production. Amidst a rapid growth trajectory, the emphasis on quality and expertise aims to ensure the delivery of safe and legal cannabis. Curaleaf International's network includes a clinic, pharmacy, and laboratory in the UK; cultivation and EU-GMP processing facilities in Portugal; an EU-GMP processing, quality assurance and research site in Spain; Four20 Pharma wholesaler and distributor in Germany; a Polish wholesaler and clinic; and the EU-GMP producer Northern Green Canada. Curaleaf International is part of Curaleaf Holdings, Inc., a leading international producer and distributor of consumer cannabis products. Media Contact:Curaleaf International:Beth Sweet-EscottHead of Communications, Curaleaf Internationalmedia@ Logo - View original content: SOURCE Curaleaf International
Forbes
21-03-2025
- Business
- Forbes
High Yields And Higher Returns: Inside The U.K. Cannabis Industry
The U.K. cannabis sector is projected to be worth nearly $570 million by 2028. Guarded by razor wire, over 1,300 alarms, and a 24/7 ex-military security presence, Dalgety's medical cannabis manufacturing facility is intentionally hard to find (I've got the Uber receipts to prove it). The 30,000-ft U.K. site saw £10m in investment and over four years of regulatory checks before shipping its first products to patients earlier this year. Head grower Brady Green has over 15 years of experience cultivating medical cannabis. He relocated from Canada in 2023, where he was at the forefront of the industry, leading a team of 450 growers at a 13-acre facility. 'I handed him [Green] a blank piece of paper and asked him to draw the perfect cannabis facility,' Dalgety's CEO, James Leavesley, tells me when I eventually arrive. Today that sketch is a reality. The site has been specifically designed to grow cannabis under highly controlled conditions, using energy-efficient lighting, cutting-edge hydroponic systems, and strict climate control to replicate the changing seasons throughout the plant's life cycle. The temperature —and the smell— get more intense as we progress through each stage of the growth cycle. In the cultivation rooms, the temperature is controlled to the nearest 0.5 ̊C and humidity to the nearest 1%, with selective use of air pressure so precise that you can see the spike in CO2 on the monitors when we exit the room. The first company to obtain an EU-GMP license for the cultivation, manufacture and supply of a medical cannabis flower API from the U.K.'s Medicines and Healthcare Regulatory Authority (MHRA), Dalgety is currently producing enough to fulfil 4,000 prescriptions per month. By 2026, when it expands to full capacity, it aims to produce 2,600 kg of cannabis per year, with yields boldly estimated to be 82% higher than the top 1% of cultivators worldwide. 'We're looking to increase our output by five and a half times by 2026,' Leavesley says. "We're setting our sights on the future and are optimistic that the market will grow quickly.' Dalgety is the first company to obtain an EU-GMP license for the cultivation, manufacture and supply ... More of a medical cannabis flower API from the MHRA. CEO James Leavesley. Dalgety stock photography 2023. Picture by Shaun Fellows / Shine Pix Ltd The U.K. is already known as the world's biggest producer and exporter of legal cannabis for medical and scientific purposes, largely due to Jazz Pharmaceuticals (formerly GW Pharma), which has manufactured the FDA-approved cannabis-based medicines, Epidiolex and Sativex, since the 90s. Since medical cannabis was legalized in 2018, several others have seen the opportunity— and growing demand— for a domestic market. Target Healthcare now manufactures Bedrocan oils in Glasgow and the North East-based Rokshaw Laboratories was taken over by Curaleaf — the world's largest cannabis company— in 2019. Along with Germany, the U.K. has been identified as a key market in the European cannabis sector, with industry analysts at Prohibition Partners, forecasting that the market will grow from $255 million in 2024 to nearly $570 million by 2028. [In the interests of full transparency, Prohibition Partners also own a media brand I write for in the U.K.] The lack of NHS access—fewer than five patients have been able to obtain a prescription through the country's national healthcare service—has paved the way for a prospering private market, with over 40 clinics now prescribing cannabis. Exact patient numbers are hard to come by — some estimates suggest there could be as many as 60,000 — while the NHS Business Services Authority, which collects data on private prescriptions, shows over 300,000 items were prescribed between April 2023-24, more than double that of the previous 12 months. In its recent U.K. report, Cannamonitor estimates that 79% of these prescriptions are for flower, with many high in THC and almost all imported from overseas. Dalgety is getting ready to meet this demand. Five new strains have been selected for market launch in 2025, with over 100 varieties in its library. The team drew on Green's experience when choosing genetics, importing 600 cannabis cuttings from the west coast of Canada (remarkably, only one didn't survive the journey). 'We worked with partners to import tissue culture cuttings so we didn't have to start with seed trials and spend a year finding genetics,' Green explains. 'Now we're diversifying. Our next step is to introduce strains that we think people will like, but don't necessarily know to exist, because it's difficult to grow so you don't find it on the illegal markets— exotic flavor profiles. We have such a small window of what we think is possible. Cannabis has the genetic potential to express every terpene on earth." Head grower Brady Green has 15 years of experience in the Canadian market. Dalgety stock photography ... More 2023. Picture by Shaun Fellows / Shine Pix Ltd All this is going on while a Labour government refuses to budge from its hard stance on cannabis. Although the Mayor of London, Sadiq Khan, proposed decriminalization back in 2022, Prime Minister Keir Starmer has made it clear he has 'no intention' of changing drug laws or treating cannabis use as a 'low-level' crime. Even calls to widen the availability of prescriptions for children with treatment-resistant epilepsy (many of whom are still unable to access the treatment at all) were shut down by Health Minister Karen Smith in the House of Commons in January— despite her previous support while in opposition. But many feel policy change is inevitable, especially given European countries including Malta, Luxembourg, Czechia, Switzerland, the Netherlands and Germany are all moving towards regulation. A recent report by Transform Drug Policy Foundation outlines how regulating cannabis for adult non-medical use in the U.K. could generate up to £1.5 billion in annual net benefits to the Treasury. The High Returns: The Economic Benefits of UK Cannabis Legalisation, report, predicts that a mature regulated market could capture up to 80% of the current illegal cannabis market within five years while creating up to 15,500 full-time jobs across cultivation, manufacturing, retail and ancillary services. Dalgety received over 2,500 applications in 48 hours in response to an advert for a 'cannabis grower" on the job search site, Indeed. The company now takes a more considered approach to hiring, with all employees required to undergo extensive background checks by the Home Office. The point still stands. With cannabis thought to be the biggest source of daily cash flow for operators in organized crime, polling suggests that in the U.K. and the U.S., the economic argument for regulation receives the most public support. Analysts at Transform believe this argument, while secondary to public health and social justice reasons, is becoming increasingly important politically, too. 'The economic dimensions of the cannabis reform debate are undoubtedly gaining political salience, particularly as governments face growing budgetary pressures,' write co-authors Ester Kincová and Steve Rolles. 'Public support for cannabis reform, particularly for economic reasons such as disrupting illegal profits and the potential tax windfall, is growing in both the U.S. and the U.K. Legal cannabis markets are expanding globally with reforms now unfolding on every continent. This global momentum, coupled with growing public support in the UK – polls show a majority favors legislation – suggests reform is increasingly likely, if not inevitable, with economic arguments potentially decisive.'
Yahoo
12-02-2025
- Business
- Yahoo
OrganiGram Holdings Inc (OGI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Net Revenue: Increased 17% to $42.7 million compared to Q1 of last year. International Sales: Grew 2.3% year over year to $3.3 million. Adjusted Gross Margin: Increased to $14.3 million or 33% from $11.2 million or 31% in the prior year period. Operating Expenses: Increased 11% to $25.1 million from $22.6 million in the prior year period. SG&A Costs: Totaled $17 million, a 7% increase from the prior year, but decreased as a percentage of net revenue from 44% to 40%. Adjusted EBITDA: $1.4 million compared to $0.1 million in the prior year period. Net Loss: $23 million compared to a net loss of $15.8 million in Q1 fiscal 2024. Cash Used by Operating Activities: $6.3 million compared to $8.1 million in the prior year period. Total Cash Position: $71.2 million, including both restricted and unrestricted cash. Capital Expenditures: Planned investment of $8 million to $10 million in sustaining capital expenditures during fiscal 2025. Warning! GuruFocus has detected 2 Warning Signs with OGI. Release Date: February 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. OrganiGram Holdings Inc (NASDAQ:OGI) achieved strong momentum as Canada's largest cannabis company by market share, with significant growth in pre-rolls and vapes. The company completed the Motif acquisition, which is expected to yield $10 million in annualized savings within 24 months, with early synergies already being realized. OrganiGram expanded its national market share by 500 basis points year over year, reflecting strategic positioning in high-growth segments. International sales grew to $3.3 million in Q1, with expectations for continued growth throughout fiscal 2025, supported by strategic investments and partnerships. The company is actively pursuing global expansion opportunities, with a focus on leveraging its strong balance sheet and strategic investments for international growth. OrganiGram faced competitive headwinds in the Edibles category, with market share declines due to low-cost single count gummies and price compression. Adjusted gross margin decreased sequentially from 37% to 33%, impacted by seasonally lower volume and competitive forces in the gummy category. Operating expenses increased by 11% to $25.1 million, primarily due to acquisition and transaction costs related to the Motif acquisition. The company reported a net loss of $23 million for the quarter, compared to a net loss of $15.8 million in Q1 fiscal 2024. There are concerns about potential oversupply in international markets, particularly in Germany, as more licensed producers enter the space. Q: Can you provide insights into your international expansion strategy, particularly regarding the EU-GMP certification and potential investments? A: Beena Goldenberg, CEO: The German medical market has grown significantly, and we have a strategic partnership with Sanity Group. We are also exploring opportunities in other medical markets like Australia, where we can export flower and potentially 2.0 products like vapes and gummies. Our EU-GMP certification will enhance our margins by eliminating middlemen. We are also considering investments in high-opportunity markets, excluding the US due to regulatory constraints. Q: Could you elaborate on the company's pro forma financials, particularly regarding revenue and EBITDA trends? A: Beena Goldenberg, CEO: We emphasize year-over-year comparisons due to seasonality. We only included three weeks of Motif's numbers in our consolidated financials, but expect significant earnings next quarter. Greg Guyatt, CFO, added that consolidated EBITDA is expected to exceed last year's, with synergies from the Motif acquisition contributing to profitability in the latter half of the year. Q: What are your thoughts on the growth potential in the German market and the impact of EU-GMP certification? A: Beena Goldenberg, CEO: The German market is growing, and our EU-GMP certification will increase demand from partners like Sanity Group. While more players are entering the market, our low-cost, high-quality product and strategic partnerships position us well. We also see opportunities in extracts and 2.0 products in markets like Australia. Q: How might the upcoming Canadian federal election impact the cannabis industry, particularly regarding excise tax reform? A: Beena Goldenberg, CEO: A new conservative government might focus on reducing crime, axing taxes, and cutting red tape, potentially benefiting the cannabis industry. We expect a harmonized national stamp and excise tax reform to strengthen the industry. If the liberals remain, a change in leadership could lead to a renewed focus on economic growth and innovation. Q: What are your expectations for the Canadian domestic market given the potential changes in government? A: Beena Goldenberg, CEO: Regardless of the election outcome, we anticipate a focus on strengthening the cannabis industry. Both potential governments may see the value in leveraging the industry for economic growth, reducing excise taxes, and supporting international expansion. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
